Pembrolizumab and Pemetrexed for Growing Chordoma
Treatments studied
Part of Cancer clinical trials.
This trial tests two drugs—pembrolizumab (Keytruda) and pemetrexed—for people with chordoma that has continued to grow. The goal is to see if the combination can slow or stop the tumor. You'll need to be in fairly good health and able to take other medicines (folic acid and vitamin B12) to protect your body from side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chordoma (a type of bone tumor) that has gotten worse in the last 6 months
- You are at least 18 years old and can do daily activities with little or no help (ECOG 0 or 1)
- You are able to take folic acid, Vitamin B12, and a steroid (dexamethasone) as part of the treatment
- You have no active autoimmune disease or serious infection, and you have not had certain cancer treatments recently (check list for timing)
- You have adequate organ function (kidney, liver, blood counts) and can take a break from NSAID pain relievers around the study drug dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies people with chordoma (a rare bone/soft-tissue tumor) and collects information and samples to learn more about the disease. It may help by improving understanding of chordoma and supporting future research.
This trial compares two standard treatment approaches—surgery versus definitive radiation—for people with a primary sacral chordoma (a bone tumor at the lower spine/pelvis area). It aims to find which approach works best for controlling the tumor while considering treatment side effects.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests whether analyzing blood and tumor samples before and after radiation and surgery can help find personalized markers for chordoma. It is for patients with chordoma of the skull base, spine, or sacrum who will receive radiation before surgery.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Hear when a new Chordoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.